Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach
Open Access
- 28 June 2024
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (12) , 5357-5369
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Lung fibrosis: Post-COVID-19 complications and evidencesInternational Immunopharmacology, 2022
- Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axisActa Pharmaceutica Sinica B, 2022
- Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementiaActa Pharmaceutica Sinica B, 2022
- SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosisCell, 2021
- Free energy perturbation (FEP)-guided scaffold hoppingActa Pharmaceutica Sinica B, 2021
- Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19Acta Pharmaceutica Sinica B, 2020
- Multiwfn: A multifunctional wavefunction analyzerJournal of Computational Chemistry, 2011
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Avoiding singularities and numerical instabilities in free energy calculations based on molecular simulationsChemical Physics Letters, 1994
- Efficient estimation of free energy differences from Monte Carlo dataJournal of Computational Physics, 1976